COVID-19 Research

Visit UCLB’s dedicated e-lucid site to access free technologies for tackling COVID-19.

Image Credit: James Tye/UCL

>

OUR TECHNOLOGIES

We market UCL innovations that have a real and positive impact on people's lives.

OUR SPINOUTS

We’re committed to supporting and nurturing our spinouts.

SUPPORT FOR RESEARCHERS

We’re ideally positioned to help and guide you at every step of your journey from innovation to impact.

What we do—

Changing the world

UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.

UCL Technology Fund announces first close of £100m Fund 2

Softscreen – a shape-shifting capsule robot for gi endoscopy

Soft Shape-shifting Capsule Robot for Endoscopy based on Eversion Navigation (SoftSCREEN). A novel design for a capsule robotic system that propels itself through the gastrointestinal (GI) tract by means of a series of continuously everting elastic tracks (i.e. the tracks go from the inside of the capsule to the outside in a continuous manner) distributed all around its body.

SnakeGrid

SnakeGrid is a way of developing low-distortion coordinate systems for large engineering projects.

Latest news and highlights

AVATAR project receives £3.37 m to systemically evaluate its therapy to help those with auditory hallucinations

28th October 2020 / UCLB News

A team of researchers will be extending the evaluation of the unique AVATAR therapy and assessing the feasibility of making ...

Top US, UK, and EU universities working together to help economies fuel post-COVID recovery

18th September 2020 / UCLB News

Ten world-leading US, UK, and EU universities will discuss with leaders in national governments and funding bodies on how to ...

Odin Vision receives NIHR funding to accelerate its AI technology for patient benefit

8th September 2020 / Spinout News

NIHR (National Institute for Health Research) has recognised Odin Vision as one of the companies to benefit from its new ...

Freeline announces pricing of initial public offering

10th August 2020 / Spinout News

Freeline Therapeutics has announced the pricing of its initial public offering in the United States of 8,823,529 American Depositary Shares ...

FIND THE RIGHT MATCH

Whether you’re an academic or looking for technologies, find your UCLB contact here.

Commercialising technology since 1993

0

Spinout companies in the UCLB portfolio

0

Active licences

0

Drug discovery projects in development

0

New UK patent applications

As of July 2019

"With UCLB's excellent advice, support and business expertise TrimTots is running and ready to roll!"

Dr Julie Lanigan, Co-Founder of TrimTots

"We could not have done this without UCLB. Their advice, guidance and expertise was invaluable"

Professor Bobby Gaspar, Chief Scientific Officer, Orchard Therapeutics

"UCLB’s input and support have been invaluable. Professional, expert and a pleasure to work with"

Professor Elizabeth Murray, Founder of HeLP Digital CIC

"UCLB are business savvy but also have a sensitive understanding of research. I am very grateful and significantly wealthier!"

Professor Anthony Finkelstein, Systemwire/Message Automation

“The valuable advice and support UCLB provided us with gave us the confidence and infrastructure to launch the Print Fair”

Professor Susan Collins, Slade School of Fine Art

“UCLB are a great source of talent, expertise and experience, and have been super helpful for us over the years”

Dr Daniel Hulme, CEO of Satalia

"UCLB's experience and advice has proved pivotal in our development as a company"

Rael Cline, CEO of MediaGamma